Seneca valley virus (SVV) cellular receptor targeted oncotherapy

Abstract

A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.

The invention claimed is: 
     
       1. A method for treating cancer, comprising:
 determining an expression level of anthrax toxin receptor 1 (ANTXR1) in a cancerous tissue from a patient, and administering to the patient an effective amount of Seneca Valley Virus (SVV) if a normal expression level or an elevated expression level of ANTXR1 is detected in the cancerous tissue. 
 
     
     
       2. The method of  claim 1 , wherein the patient is a patient with small cell lung cancer, neuroblastoma, retinoblastoma, medulloblastoma, rhabdomyosarcoma or pediatric neuroendocrine solid tumor. 
     
     
       3. The method of  claim 1 , wherein the patient is a patient with small cell lung cancer. 
     
     
       4. The method of  claim 1 , wherein the expression level of ANTXR1 in the cancerous tissue is determined at transcriptional level. 
     
     
       5. The method of  claim 1 , wherein the expression level of ANTXR1 in the cancerous tissue is determined at translational level. 
     
     
       6. The method of  claim 1 , further comprising:
 determining the expression level of one or more biomarkers in an innate immune response pathway in the cancerous tissue; and 
 administering to the patient an effective amount of SVV if (1) a normal expression levels or an elevated expression levels of ANTXR1 is detected in the cancerous tissue and (2) a decreased expression level of one or more biomarkers in the innate immune response pathway is detected in the cancerous tissue. 
 
     
     
       7. The method of  claim 6 , wherein the innate immune response pathway is an α-interferon or a β-interferon pathway. 
     
     
       8. The method of  claim 1 , wherein the SVV is administered in combination with another therapeutic agent. 
     
     
       9. The method of  claim 8 , wherein the therapeutic agent is selected from the group consisting of checkpoint inhibitors, cytokines, growth factors, photosensitizing agents, radionuclides, toxins, siRNA molecules, signaling modulators, anti-cancer antibiotics, anticancer antibody, angiogenesis inhibitors, chemotherapeutic compound, antimetastatic compound and a combination of any thereof. 
     
     
       10. The method of  claim 9 , wherein the therapeutic agent is a checkpoint inhibitor. 
     
     
       11. The method of  claim 1 , wherein the SVV is administered by direct injection into the cancerous tissue.